RxDoctor Payments Data

Otashe Golden, MD

Family Medicine · Modesto, CANPI 1508891797

Payments from drug & device makers

$630in general payments, 2019–2025

Across 35 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$255
  • Johnson & Johnson$103
  • UCB, Inc.$77
  • AstraZeneca$35
  • Merck$34
  • Pfizer$30
  • plus $95 from 6 others

What the payments were for

  • Food & beverage$630100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$630 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$82,226
Medicare patients
261
Services billed
793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$79,483
TrulicityDulaglutide133$71,603
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$46,712
JardianceEmpagliflozin68$19,540
AptiomEslicarbazepine Acetate31$19,398
GemtesaVibegron74$17,770
JanuviaSitagliptin Phosphate45$13,134
TradjentaLinagliptin47$12,778
SantylCollagenase Clostridium Hist.25$12,683
Breo ElliptaFluticasone/Vilanterol27$11,789
Atorvastatin Calcium827$10,607
Incruse ElliptaUmeclidinium Bromide27$10,347
XareltoRivaroxaban36$10,277
Lagevrio (Eua)Molnupiravir11$10,205
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog112$10,036

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$30$84,894283 claims
MerckJanuvia, Lagevrio (Eua)$34$23,33856 claims
Sunovion Pharmaceuticals Inc.Aptiom$16$19,39831 claims
Smith+NephewSantyl$14$12,68325 claims
Johnson & JohnsonXarelto$103$10,27736 claims
AbbVieLinzess$16$6,99212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →